GLONGHUI, September 29 | JD Health (6618.HK) rose more than 6% to HK$40, with a total market value of HK$127.213 billion. Goldman Sachs recently published a report stating that in response to JD Health's mid-term performance and sluggish consumer market, the company's adjusted net profit forecast for the 2023-2026 fiscal year was lowered by up to 5%. The revenue growth forecast was more cautious, but this was partly offset by improved profit margins. The target price was raised from HK$74 to HK$76 to maintain the buying rating.